Abstract
The benefit of aspirin among patients with stable atherosclerosis without a prior ischemic event is not well defined. Aspirin would be of benefit in outpatients with atherosclerosis with prior ischemic events, but not in those without ischemic events. Subjects from the Reduction of Atherothrombosis for Continued Health registry were divided according to prior ischemic event (n =21 724) vs stable atherosclerosis, but no prior ischemic event (n = 11 872). Analyses were propensity score matched. Aspirin use was updated at each clinic visit and considered as a time-varying covariate. The primary outcome was the first occurrence of cardiovascular death, myocardial infarction, or stroke. In the group with a prior ischemic event, aspirin use was associated with a marginally lower risk of the primary outcome at a median of 41 months (hazard ratio [HR]: 0.81, 95% confidence interval [CI]: 0.65-1.01, P = 0.06). In the group without a prior ischemic event, aspirin use was not associated with a lower risk of the primary outcome at a median of 36 months (HR: 1.03, 95% CI: 0.73-1.45, P = 0.86). In this observational analysis of outpatients with stable atherosclerosis, aspirin was marginally beneficial among patients with a prior ischemic eve...Continue Reading
References
Dec 12, 1992·Lancet·S Juul-MöllerR Omblus
May 15, 1991·Annals of Internal Medicine·P M RidkerC H Hennekens
Feb 15, 1980·JAMA : the Journal of the American Medical Association
Jan 8, 1994·BMJ : British Medical Journal
Nov 5, 1998·Statistics in Medicine·R B D'Agostino
Sep 14, 1999·Journal of the American College of Cardiology·M S LauerE J Topol
Dec 24, 2005·American Journal of Epidemiology·Tobias KurthJames M Robins
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Mar 30, 2006·American Heart Journal·E Magnus OhmanUNKNOWN REACH Registry Investigators
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Jan 12, 2008·The American Journal of Medicine·Jeffrey S BergerRichard C Becker
Sep 2, 2010·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Sep 8, 2010·Lancet·Shamir R MehtaUNKNOWN CURRENT-OASIS 7 trial investigators
Aug 6, 2011·Multivariate Behavioral Research·Peter C Austin
Nov 5, 2011·Circulation·Sidney C SmithUNKNOWN World Heart Federation and the Preventive Cardiovascular Nurses Association
Mar 24, 2012·Lancet·Peter M RothwellTom W Meade
Oct 4, 2012·JAMA : the Journal of the American Medical Association·Sripal BangaloreUNKNOWN REACH Registry Investigators
May 3, 2013·Cleveland Clinic Journal of Medicine·Ki Park, Anthony A Bavry
Sep 3, 2013·European Heart Journal·UNKNOWN Task Force MembersJose Luis Zamorano
Sep 2, 2014·Recent Patents on Cardiovascular Drug Discovery·Islam Y ElgendyCharles R Conti
Dec 3, 2014·The American Journal of Medicine·Anthony A BavryCarl J Pepine
Apr 3, 2016·BMC Medical Research Methodology·David HajageYann De Rycke
May 18, 2016·Circulation·Zhu-Ming ZhangElsayed Z Soliman
May 23, 2016·Lancet·Peter M RothwellZiyah Mehta
Jul 29, 2016·Clinical Cardiology·Larry R JacksonRamón Corbalán
Citations
Oct 26, 2018·PloS One·Sheau C ChaiBahram H Arjmandi
Jun 4, 2019·World Journal of Surgical Oncology·Yasunori YoshimotoTsunenori Yamamoto
Jun 11, 2020·Advances in Therapy·Erkki SoiniAurelie Millier
Jan 9, 2021·Trials·Jiachuan XiongJinghong Zhao
Mar 13, 2021·The American Journal of Cardiology·Deepak L Bhatt, Charles V Pollack